Research Article
Prevalence of ESBL urinary tract infection in children
Galia ZA Awean, Khalil Salameh*, Hala Elmohamed, Hoor Alshmayt and Mohamed Riad Bur Omer
Published: 08/08/2019 | Volume 2 - Issue 1 | Pages: 004-007
Background
Urinary tract infection (UTI) is one of the extremely popular causes of febrile illness in children, demanding antimicrobial therapy [1]. Overall, 8% of females and 2% of males, experience at least one incident of UTI by seven years of age, and recurrence takes place in up to 30% during a year [2].
Escherichia Coli has been known as the commonest causative organism of the majority of urinary tract infections in children with prevalence ranging from 80-90% [3]. Extended-spectrum beta-lactamases (ESBL) are enzymes produced by Gram-Negative Bacilli (GNB), accountable for fighting against penicillin, cephalosporin and aztreonam [4].
Read Full Article HTMLDOI: 10.29328/journal.japch.1001004Cite this Article
References
- Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005; 18: 417–422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15831830
- Desai DJ, Gilbert B, McBride CA. Pediatric urinary tract infections: Diagnosis and treatment. Aust Fam Physician. 2016; 45: 558–563.
- Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front Cell Infect Microbiol. 2015; 5: 45. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26075187
- Cantón R, Valverde A, Novais A, Baquero F, Coque T. Evolution and current situation of ESBL. Enferm Infecc Microbiol Clin. 2007; 25: 2–10.
- Bonnet R. Growing group of extended spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004; 48: 1-14.
- Falagas ME, Karageorgopoulos DE. Extended spectrum β-lactamase-producing organisms. J Hosp Infect. 2009; 73: 345-354. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19596491
- Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, et al. Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007; 60: 1018-1029. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17855724
- García-Hernández AM, García-Vázquez E, Hernández-Torres A, Ruiz J, Yagüe G, et al. Bacteraemia due to Escherichia coli producing extended-spectrum beta-lactamases (ESBL): clinical relevance and today’s insights]. Rev Esp Quimioter. 2011; 24: 57–66. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21666996
- Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007; 60: 913–920. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17848376
- Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987; 9: 1065-1078. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/3321356
- Colodner R, Rock W, Chazan B, Keller N, Guy N, et al. Risk factors for the development of extended-spectrum betalactamase- producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004; 23: 163–167. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14986159
- CLSI. Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute. 2009.
- Shettigar SCG, Roche R, Nayak N, Anitha KB, Soans S. Bacteriological profile, antibiotic sensitivity pattern, and detection of extended-spectrum β-lactamase in the isolates of urinary tract infection from children. J Child Health. 2016; 3: 5.
- Pourakbari B, Ferdosian F, Mahmoudi S, Teymuri M, Sabouni F, et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol. 2012; 43: 766–769. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24031888
- Rezai MS, Salehifar E, Rafiei A, Langaee T, Rafati M, et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int. 2015; 2015: 309478. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26064896
- Moore CE, Sona S, Poda S, Putchhat H, Kumar V, et al. Antimicrobial susceptibility of uropathogens isolated from Cambodian children. Paediatr Int Child Health. 2016: 36: 113-117. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25704569
- Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, et al. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012; 54: 858–862. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22882781
- López-Cerero L, Pascual A. Epidemiology of ESBL in the community. An increasing problem. Enferm Infecc Microbiol Clin. 2007; 25: 23–28.
- Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, et al. Susceptibility of European ESCHERICHIA COLI clinical isolates from intra-abdominal infections, extended-spectrum betalactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clin Microbiol Infect. 2012; 18: 253–259.
- Rodríguez-Banño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing ESCHERICHIA COLI in nonhospitalized patients. J Clin Microbiol. 2004; 42: 1089–1094. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15004058
- Pediatric Urinary Tract Infection Organism-Specific Therapy. Updated: 2015.














